Piperacillin/tazobactam, at a dosage of 4g/500 mg every 8 h, was administered intravenously to 217 patients with complicated urinary tract infections. The most common diagnosis was pyelonephritis. The most common pathogen wasEscherichia coli (47%) followed byPseudomonas aeruginosa (13%), and enterococci (8%). Among clinically evaluable patients, 86% (115/134) were cured or improved at the study endpoint and 14% (19/134) were clinical failures or relapsed. Among bacteriologically evaluable patients, 85% (95/112) had a favorable clinical response at endpoint. The bacteriological response rate was 73% (82/112) at endpoint. Overall, 82% of all pathogens were eradicated. Therapy was associated with a low incidence of side effects, and adverse experience were mild and of short duration.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Cooksey R, Swenson J, Clark N, Gay E, Thornsberry C (1990) Patterns and mechanisms of β-lactam resistance amongst isolates ofEscherichia coli from hospitals in the United States. Antimicrob Agents Chemother 34:739–745
Eliopoulos GM, Klimm K, Ferraro MJ, Jacoby GA, Moellering RC Jr (1989) Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 12:481–488
Fortner CL, Finley RS, Schimpff SC (1982) Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions. Pharmacotherapy 2:287–299
Gooding PG, Clark BJ, Sathe SS (1982) Piperacillin: a review of clinical experience. J Antimicrob Chemother 9 [Suppl B]:93–99
Gutmann L, Kitzis MO, Yamabe S, Acar JF (1986) Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases. Antimicrob Agents Chemother 29:955–957
Jacoby GA, Sutton L (1985) β-lactamases and β-lactam resistance inEscherichia coli. Antimicrob Agents Chemother 28:703–706
Kuck NA, Jacobus NV, Peterson PJ, Weiss WJ, Testa RA (1989) Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother 33:1964–1969
Kwung P, Fu H, Neu C (1978) Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother 358–367
Sabath LD, Elder HA, McCall CE, Finland M (1976) Synergistic combinations of penicillins in the treatment of bacteriuria. N Engl J Med 277:232–238
About this article
Cite this article
Nowé, P. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Med 20, S39–S42 (1994). https://doi.org/10.1007/BF01745250
- Urinary tract infections